Amid a generally buoyant European stock market, with France's CAC 40 Index recently marking a modest rise, investors continue to seek opportunities that combine growth potential with strong insider commitment. In this context, companies on the Euronext Paris that exhibit high insider ownership and significant revenue increases present an intriguing proposition for those looking to align with the interests of core stakeholders in a thriving economic environment.

Top 10 Growth Companies With High Insider Ownership In France

Name Insider Ownership Earnings Growth VusionGroup (ENXTPA:VU) 13.5% 25.2% Groupe OKwind Société anonyme (ENXTPA:ALOKW) 24.8% 30.8% Adocia (ENXTPA:ADOC) 11.9% 63% Icape Holding (ENXTPA:ALICA) 30.2% 26.2% La Française de l'Energie (ENXTPA:FDE) 20.1% 31.9% Arcure (ENXTPA:ALCUR) 21.4% 27.5% S.M.A.I.O (ENXTPA:ALSMA) 17.3% 35.2% Munic (ENXTPA:ALMUN) 29.4% 149.2% MedinCell (ENXTPA:MEDCL) 16.4% 69.6% OSE Immunotherapeutics (ENXTPA:OSE) 25.6% 5.9%

Click here to see the full list of 21 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Lectra

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA specializes in industrial intelligence solutions for the fashion, automotive, and furniture industries across Northern Europe, Southern Europe, the Americas, and Asia Pacific, with a market capitalization of approximately €1.10 billion.

Operations: The company generates revenue from the Americas and Asia Pacific regions, totaling approximately €170.33 million and €110.28 million respectively.

Insider Ownership: 19.6%

Revenue Growth Forecast: 11.3% p.a.

Lectra, a French company with significant insider ownership, shows promise in its growth trajectory despite recent earnings dips. In Q1 2024, Lectra reported sales of €129.56 million and a slight decrease in net income to €7.17 million. Analysts forecast Lectra's earnings to grow significantly at 28.6% annually over the next three years, outpacing the broader French market's expected 10.9%. Additionally, revenue is projected to increase by 11.3% annually, also above the national average of 5.7%. Despite these positives, return on equity is anticipated to remain low at 13.3%, and the stock is currently valued at 33.6% below its estimated fair value.

Unlock comprehensive insights into our analysis of Lectra stock in this growth report. The analysis detailed in our Lectra valuation report hints at an deflated share price compared to its estimated value. ENXTPA:LSS Earnings and Revenue Growth as at Jul 2024

MedinCell

Simply Wall St Growth Rating: ★★★★★☆



Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable treatments across various therapeutic areas, with a market capitalization of approximately €424.28 million.

Operations: The company generates its revenue primarily from the pharmaceuticals segment, totaling €11.95 million.

Insider Ownership: 16.4%

Revenue Growth Forecast: 43.8% p.a.

MedinCell, a French growth company with high insider ownership, is navigating a challenging phase with significant revenue growth expected at 43.8% annually. Despite recent setbacks in clinical trials, such as the Phase 3 trial for F14 not meeting its primary endpoint, MedinCell remains on track to profitability within three years. The company's share price has been highly volatile recently, reflecting investor reactions to both its financial results and clinical developments. While shareholder dilution occurred last year, MedinCell's innovative pipeline and strategic presentations at global conferences underscore its potential in the biopharmaceutical sector.

Take a closer look at MedinCell's potential here in our earnings growth report. Our valuation report here indicates MedinCell may be overvalued. ENXTPA:MEDCL Earnings and Revenue Growth as at Jul 2024

VusionGroup

Simply Wall St Growth Rating: ★★★★★★

Overview: VusionGroup S.A. specializes in offering digitalization solutions for commerce across Europe, Asia, and North America, with a market capitalization of approximately €2.19 billion.

Operations: VusionGroup's revenue is primarily derived from installing and maintaining electronic shelf labels, generating €801.96 million.

Insider Ownership: 13.5%

Revenue Growth Forecast: 21.9% p.a.

VusionGroup, a French growth company with high insider ownership, has demonstrated robust financial performance with earnings and revenue growth significantly outpacing the market at 25.24% and 21.9% per year respectively. Despite a highly volatile share price recently, analysts project substantial upside potential with an expected price increase of 41.7%. Recent deployments like the digital solutions for Hy-Vee highlight VusionGroup's innovative edge in retail technology, enhancing operational efficiency and customer service while reducing waste and carbon footprint through its VusionCloud platform.

Click here to discover the nuances of VusionGroup with our detailed analytical future growth report. The analysis detailed in our VusionGroup valuation report hints at an inflated share price compared to its estimated value. ENXTPA:VU Ownership Breakdown as at Jul 2024

Next Steps

Click here to access our complete index of 21 Fast Growing Euronext Paris Companies With High Insider Ownership. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ENXTPA:LSS ENXTPA:MEDCLENXTPA:VU

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]